Cite
HARVARD Citation
Zarca, D. et al. (n.d.). P166 Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France. Breast. pp. S79-S80. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zarca, D. et al. (n.d.). P166 Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France. Breast. pp. S79-S80. [Online].